A need for a new business model?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: A need for a new business model?
Released on: December 18, 2015. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Flic Gabbay, CEO of TranScrip Partners, discusses how the new collaborative approach to drug discovery and development could be forcing biopharmaceutical companies to turn away from traditional corporate models.
  • Summary
  • Transcript
  • Participants
  • Company
Flic Gabbay, CEO of TranScrip Partners, discusses how the new collaborative approach to drug discovery and development could be forcing biopharmaceutical companies to turn away from traditional corporate models.
Flic Gabbay, CEO of TranScrip Partners, discusses how the new collaborative approach to drug discovery and development could be forcing biopharmaceutical companies to turn away from traditional corporate models.
Flic is the Managing Partner of TranScrip Partners of which she was a co-founder in 2008 and has worked in the industry for more than 30 years. She has held a number of senior and CEO positions in both big pharma, biotech and CROs. She is one of TranScrip’s specialists in infectious disease, respiratory and pre and peri-registration drug safety. Flic has held senior positions in pharma and bio-tech companies in Europe and North America and worked on a range of projects including small molecules and biologicals. She has worked on antibiotics, antifungals, respiratory, anti-inflammatories, lipid lowering agents, renal disease and oncology and has co-led many successful license applications including five she has worked on and defended within TranScrip. In 1990, Flic founded Gabbay Group, a CRO acquired by PPD where she was Global VP for Regulatory and Clinical Research. She has also been CEO of two small biotech companies, Director of Education at the Drug Safety Research Unit in Southampton and Chairman of the steering group that set-up the UK Faculty of Pharmaceutical Medicine (FPM) and, for nine years, was its Academic Registrar founder.
TranScrip is a trusted partner in providing strategic leadership and operational capacity for over 100 companies globally. Our clients include 20 of the top 50 pharmaceutical and many smaller biopharma companies. TranScrip supports the development and lifecycle management of biopharmaceutical products. We provide expertise, resourcing and strategic oversight from translational medicine to successful registration and market access.